You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD19 target

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary CNS Lymphoma Trial in London (CD19CAR T-cells)

Recruiting
  • Primary CNS Lymphoma
  • CD19CAR T-cells
  • London, United Kingdom
    University College London Hospital
Jun 13, 2022

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

CAR-T Cell Therapy Trial in Shanghai (GC012F injection)

Recruiting
  • CAR-T Cell Therapy
  • GC012F injection
  • Shanghai, Shanghai, China
    Department of Rheumatology, Ren Ji Hospital South Campus, School
May 5, 2023

B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified Trial in Guangzhou, Guanzhou (CD19 CAR T-Cell(CAT19T2))

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-Cell Lymphoma, Unspecified
  • CD19 CAR T-Cell(CAT19T2)
  • Guangzhou, Guangdong, China
  • +1 more
Nov 4, 2022

B-cell Non-Hodgkin's Lymphoma Trial (Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
  • (no location specified)
Oct 12, 2021

Leukemia Trial in Beijing (IM19 CAR-T)

Unknown status
  • Leukemia
  • IM19 CAR-T
  • Beijing, Beijing, China
    Peking University people's hospita
Dec 15, 2020

Lymphoma, B-Cell, Relapse/Recurrence, Refractory Lymphoma Trial in Shenzhen (dual target CAR-T cell therapy)

Unknown status
  • Lymphoma, B-Cell
  • +3 more
  • dual target CAR-T cell therapy
  • Shenzhen, Guangdong, China
    Shenzhen University General hospital
Jan 23, 2021

Dual-target CAR-T Cells, B ALL, Relapse Trial in Shenzhen (Dual target CAR-T cell therapy)

Unknown status
  • Dual-target CAR-T Cells
  • +3 more
  • Dual target CAR-T cell therapy
  • Shenzhen, Guangdong, China
    Shenzhen University General hospital
Jan 23, 2021

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

Acute Myeloid Leukemia Trial in Ramat Gan (CAR-T CD19)

Recruiting
  • Acute Myeloid Leukemia
  • CAR-T CD19
  • Ramat Gan, Israel
    Chaim Sheba Medical Center
Oct 30, 2022

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • regimen with BTK inhibitor +Anti-CD19 CAR T cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023

Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)

Not yet recruiting
  • Systemic Lupus Erythematosus
  • CD19 CAR-T cell infusion
  • (no location specified)
Oct 24, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Cyclophosphamide (Non-IMP, Lymphodepletion)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +4 more
Jul 24, 2023

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Solid Tumor, Adult Trial (CF33-CD19 IT, CF33-CD19 IV, Blinatumomab)

Not yet recruiting
  • Solid Tumor, Adult
  • CF33-CD19 IT
  • +2 more
  • (no location specified)
Sep 26, 2023

Graft Vs Host Disease, Graft-versus-host-disease, Acute Myeloid Leukemia Trial (CliniMACS® device)

Not yet recruiting
  • Graft Vs Host Disease
  • +5 more
  • CliniMACS® device
  • (no location specified)
Jul 20, 2023

Systemic Lupus Erythematosus Trial (CD19 Universal CAR-?d T Cells)

Not yet recruiting
  • Systemic Lupus Erythematosus
  • CD19 Universal CAR-γδ T Cells
  • (no location specified)
Oct 24, 2023